News | November 10, 2025
Zydus Lifesciences posts Q2 FY26 PAT at Rs. 1,258.6 Cr
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Budesonide is indicated for mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in adults and children 8 years of age and olde
With over two decades of extensive experience, Lal has established himself as a transformational leader in the FMCG and consumer goods sectors
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ
Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older
Zydus Pinkathon will be led by women to raise awareness on breast cancer and women's health
Subscribe To Our Newsletter & Stay Updated
